GlassScriptPhysician profile
Lashonda Spencer
NPI 1902904824
$122,658.62
in general payments reported to CMS, 2019-2025
9 companies · $40K in 2025
The $40K reported for 2025 was more than what 94% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $5,399 · 2021: $10K · 2022: $8,670 · 2023: $21K · 2024: $14K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $16K · Travel and Lodging: $7,301 · Food and Beverage: $4,357 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,710.00 |
| Consulting Fee | $16,310.00 |
| Travel and Lodging | $7,300.76 |
| Food and Beverage | $4,357.25 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $111,912.64 | 2019-2025 | Biktarvy, Yeztugo, Sunlenca |
| Janssen Scientific Affairs, LLC | $6,500.00 | 2021 | |
| Theratechnologies INC. | $2,500.00 | 2022 | |
| Viiv Healthcare Company | $1,377.78 | 2019-2025 | Apretude, Cabenuva |
| Janssen Biotech, INC. | $153.26 | 2020-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $85.44 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $56.54 | 2024 | Pifeltro, Delstrigo |
| Janssen Products, LP | $54.99 | 2020 | |
| Pfizer INC. | $17.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lashonda Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.